About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. The company's lead product, ADX-102, is an aldehyde trap in development for ocular and systemic inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism.

Press Releases

Feb 21, 2018
Jan 30, 2018
Nov 29, 2017
Nov 9, 2017
Nov 7, 2017

Corporate Presentation


Scientific Posters & Presentations